Medafor
Bard’s Medafor wins injunction against CryoLife’s PerClot Topical
CryoLife to cash in on Bard buyout of Medafor
CryoLife Inc. (NYSE:CRY) said it’s in line for a $15.1 million payout from the C.R. Bard (NYSE:BCR) acquisition of Minnesota-based Medafor for up to $280 million.
Bard puts a ribbon on $280M Medafor acquisition
Medafor agrees to Bard buyout worth up to $280M
C.R. Bard (NYSE:BCR) said it agreed to pay $200 million up front and another possible $80 million for Medafor and its line of anti-bleeding agents.
Minneapolis-based Medafor makes plant-based hemostatic agents including the Arista MPH agent, which won CE Mark approval in the European Union in 2003 and garnered FDA approval for surgical use in 2006.